Jeffrey Kaine

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate

Stanley Cohen, Grant W. Cannon, Michael Schiff et al. · Arthritis & Rheumatism · 2001 · 297 citations

Rheumatoid Disorder, Rheumatology, Active Ra +11

Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.

Jeffrey Kaine, Alan Kivitz, C. Birbara et al. · PubMed · 2007 · 243 citations

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study

Mark C. Genovese, Jeffrey Kaine, Mitchell B. Lowenstein et al. · Arthritis & Rheumatism · 2008 · 203 citations